![](https://cdn.statically.io/img/www.statnews.com/wp-content/uploads/2023/08/unnamed-1-645x645.jpeg)
Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs. Doctors are getting letters from insurance investigators discouraging new prescriptions. And pharmacies are being told by insurers to check for a specific diagnosis when filling prescriptions.
It’s a charge on all fronts by insurance companies to contain the spiraling costs of a new class of weight loss-inducing drugs, the GLP-1s.
Some of these treatments — like Novo Nordisk’s Wegovy — are approved for obesity, while others — like Novo’s Ozempic and Eli Lilly’s Mounjaro — are approved for diabetes, but they all employ similar mechanisms and have exploded in demand for their ability to curb appetite and cut significant amounts of weight.
![STAT+](https://cdn.statically.io/img/www.statnews.com/wp-content/uploads/2022/02/stat_plus_hero_new-2048x502.png)
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect